Trial ID or NCT#

NCT01477463

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine the signaling pathways and changes in gene expression in melanocytes of subjects with a history of non-melanoma skin cancer who are exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral vitamin D could be explored further as a chemoprevention for melanoma skin cancer.

Official Title

Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Paul A. Khavari, MD, PhD
Paul A. Khavari, MD, PhD
Dermatologist, Cutaneous oncology specialist, Medical oncologist
Carl J. Herzog Professor in Dermatology in the School of Medicine

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061